BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260516T003800
CREATED:20231123T125135Z
LAST-MODIFIED:20231123T125201Z
UID:38203-1710720000-1710979199@www.pharmajournalist.com
SUMMARY:7th Antigen-Specific Immune Tolerance Drug Development Summit
DESCRIPTION:Returning for the seventh year\, the 7th Antigen-Specific Immune Tolerance Summit (March 18 – 20\, 2024 | Boston\, MA) will lean into the industry’s key challenges from details of T-cell assays in preclinical and larger clinical studies; to pioneering CAR-Treg\, mRNA-LNP\, biologic\, peptide\, approaches and updates on proof-of-concept and ongoing clinical programs. This is the highest value meeting on the immune tolerance community’s conference calendar. \nThis is your comprehensive guide to define your pipeline and therapeutic development strategy for 2023\, delve into your opportunity to create tolerizing\, curative\, strategies for autoimmunity\, and tap into your tolerance strategy to tackle immunogenicity and transform the biologic landscape. Network with large pharma scouts\, industry super-giants\, and biotech pioneers to build meaningful partnerships and gather insights beyond the literature. \nExpect to be involved in interactive discussions on: \n\nTackle antigen-selection and deepen your understanding of the role of T-cells\, B-cells and T-regs in immune tolerance evaluate strategies and technologies in complex heterogenous disease settings with COUR Pharmaceuticals and Pfizer.\nBuild the biomarker toolbox and engage in discussions around the true markers of ‘tolerance’ for practical tolerance strategies and markers for determinants of efficacy\, patient selection\, and therapeutic durability with Takeda\, University of Pittsburgh\, Imcyse\, and Anokion\nAssess toxicity and durability of tolerance therapeutics using preclinical models to inform the frequency of administration and the persistence or loss of tolerance over time with Toleranzia and University of Helsinki\nEvaluate delivery technologies and novel approaches including CAR-Treg\, mRNA-LNP\, biologics\, and more to propel tolerizing therapies through proof-of-concept to the clinic with Sonoma\, Moderna\, and Integrated Nanotherapeutics\nHarness mechanistic models and autoimmune disease models to highlight efficacious tolerance induction across diseases including Celiac\, Type 1 Diabetes\, Multiple Sclerosis\, Rheumatoid Arthritis\, and more with GRO Bioscience\, RheumaGen\, NexImmune\, and Parvus Therapeutics\n\nJoin 110+ autoimmune and immunologist scientists\, corporate strategists\, and large pharma scouts at this timely and comprehensive summit set to unite the immune tolerance field. From innovative\, start-up biotechs to big pharma super giants\, this is your unique opportunity to discuss advancing efficacious antigen- and drug-specific tolerance approaches to patients in need. \nDownload the full agenda here to see our full speaker faculty\, 3-day agenda and audience breakdown: https://ter.li/7teig8
URL:http://www.pharmajournalist.com/event/7th-antigen-specific-immune-tolerance-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260516T003800
CREATED:20240213T100720Z
LAST-MODIFIED:20240213T100720Z
UID:38674-1710720000-1710979199@www.pharmajournalist.com
SUMMARY:9th Innate Killer Summit 2024
DESCRIPTION:“The translational impact and nature of the work that was being presented were outstanding. You get a lot of insights from your peers regarding their experience interacting with the regulatory agencies” – ONK Tx \nThe 9th Innate Killer Summit is designed for experts striving to realize the clinical potential of NK–based therapies from early discovery to later stages in the clinic through 3 dedicated tracks of content: Pre-clinical\, Clinical Translation\, CMC & Process Development. \nSpecifically focussing on advancing NK engager\, bispecific\, cell therapy\, and combination therapy approaches to improve the clinical durability and streamlining manufacturing. Come together with industry experts to brainstorm best approaches to enhance efficacy and persistence as well as reduce the cost of production. \nCollaborating closely with pioneers such as Dan Kaufman\, Evren Alici\, and industry experts from Zelluna Immunotherapy\, Artiva Biotherapeutics\, Affimed\, Sanofi\, Immunity Bio\, Cytovia (to name a few!) to ensure the critical priorities of the field are captured. Join to gain practical takeaways for novel techniques in engineering NK cells while preserving cell fitness\, best practice clinical trial design methods\, benefits of feeder-free cell expansion and many more! \nRanging from a jam-packed pre-conference workshop day with 6 different workshops and a bootcamp ranging from preclinical to CMC and process development. Also up for offer are 10+ plenary talks across the main conference days where experts will guide you through the current cell therapy landscape\, an industry leaders annual briefing\, a range of clinical data presentations\, and an investors panel!
URL:http://www.pharmajournalist.com/event/9th-innate-killer-summit-2024/
LOCATION:San Diego Marriott Del Mar\, 11966 El Camino Real\, San Diego\, CA\, 92130\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR